['\xe2\x86\x91 = INCREASE, \xe2\x86\x93 = DECREASE, \xe2\x86\x94 = NO CHANGE', 'HIV-ANTIVIRAL AGENTS: NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)', 'DIDANOSINE THE INTERACTION BETWEEN EDURANT AND THE DRUG WAS EVALUATED IN A CLINICAL STUDY. ALL OTHER DRUG-DRUG INTERACTIONS SHOWN ARE PREDICTED. THIS INTERACTION STUDY HAS BEEN PERFORMED WITH A DOSE HIGHER THAN THE RECOMMENDED DOSE FOR EDURANT ASSESSING THE MAXIMAL EFFECT ON THE CO-ADMINISTERED DRUG. THE DOSING RECOMMENDATION IS APPLICABLE TO THE RECOMMENDED DOSE OF EDURANT 25 MG ONCE DAILY.', '\xe2\x86\x94 RILPIVIRINE \xe2\x86\x94 DIDANOSINE', 'NO DOSE ADJUSTMENT IS REQUIRED WHEN EDURANT IS CO-ADMINISTERED WITH DIDANOSINE. DIDANOSINE IS TO BE ADMINISTERED ON AN EMPTY STOMACH AND AT LEAST TWO HOURS BEFORE OR AT LEAST FOUR HOURS AFTER EDURANT (WHICH SHOULD BE ADMINISTERED WITH A MEAL).', 'HIV-ANTIVIRAL AGENTS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)', 'NNRTI (DELAVIRDINE)', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 DELAVIRDINE', 'IT IS NOT RECOMMENDED TO CO-ADMINISTER EDURANT WITH DELAVIRDINE AND OTHER NNRTIS.', 'OTHER NNRTIS (EFAVIRENZ, ETRAVIRINE, NEVIRAPINE)', '\xe2\x86\x93 RILPIVIRINE \xe2\x86\x94 OTHER NNRTIS', '', 'HIV-ANTIVIRAL AGENTS: PROTEASE INHIBITORS (PIS)-BOOSTED (I.E., WITH CO-ADMINISTRATION OF LOW-DOSE RITONAVIR) OR UNBOOSTED (I.E., WITHOUT CO-ADMINISTRATION OF LOW-DOSE RITONAVIR)', 'DARUNAVIR/RITONAVIR', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 BOOSTED DARUNAVIR', 'CONCOMITANT USE OF EDURANT WITH DARUNAVIR/RITONAVIR MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). NO DOSE ADJUSTMENT IS REQUIRED WHEN EDURANT IS CO-ADMINISTERED WITH DARUNAVIR/RITONAVIR.', 'LOPINAVIR/RITONAVIR', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 BOOSTED LOPINAVIR', 'CONCOMITANT USE OF EDURANT WITH LOPINAVIR/RITONAVIR MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). NO DOSE ADJUSTMENT IS REQUIRED WHEN EDURANT IS CO-ADMINISTERED WITH LOPINAVIR/RITONAVIR.', 'OTHER BOOSTED PIS (ATAZANAVIR/RITONAVIR, FOSAMPRENAVIR/RITONAVIR, SAQUINAVIR/RITONAVIR, TIPRANAVIR/RITONAVIR)', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 BOOSTED PI', 'CONCOMITANT USE OF EDURANT WITH BOOSTED PIS MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). EDURANT IS NOT EXPECTED TO AFFECT THE PLASMA CONCENTRATIONS OF CO-ADMINISTERED PIS.', 'UNBOOSTED PIS (ATAZANAVIR, FOSAMPRENAVIR, INDINAVIR, NELFINAVIR)', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 UNBOOSTED PI', 'CONCOMITANT USE OF EDURANT WITH UNBOOSTED PIS MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). EDURANT IS NOT EXPECTED TO AFFECT THE PLASMA CONCENTRATIONS OF CO-ADMINISTERED PIS.', 'OTHER AGENTS', 'ANTACIDS: ANTACIDS (E.G., ALUMINUM OR MAGNESIUM HYDROXIDE, CALCIUM CARBONATE)', '\xe2\x86\x94 RILPIVIRINE (ANTACIDS TAKEN AT LEAST 2 HOURS BEFORE OR AT LEAST 4 HOURS AFTER RILPIVIRINE)', 'THE COMBINATION OF EDURANT AND ANTACIDS SHOULD BE USED WITH CAUTION AS CO-ADMINISTRATION MAY CAUSE SIGNIFICANT DECREASES IN RILPIVIRINE PLASMA CONCENTRATIONS (INCREASE IN GASTRIC PH). ANTACIDS SHOULD ONLY BE ADMINISTERED EITHER AT LEAST 2 HOURS BEFORE OR AT LEAST 4 HOURS AFTER EDURANT.', '', '\xe2\x86\x93 RILPIVIRINE (CONCOMITANT INTAKE)', '', 'AZOLE ANTIFUNGAL AGENTS : FLUCONAZOLE ITRACONAZOLE KETOCONAZOLE POSACONAZOLE VORICONAZOLE', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x93 KETOCONAZOLE', 'CONCOMITANT USE OF EDURANT WITH AZOLE ANTIFUNGAL AGENTS MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). NO RILPIVIRINE DOSE ADJUSTMENT IS REQUIRED WHEN EDURANT IS CO-ADMINISTERED WITH AZOLE ANTIFUNGAL AGENTS. CLINICALLY MONITOR FOR BREAKTHROUGH FUNGAL INFECTIONS WHEN AZOLE ANTIFUNGALS ARE CO-ADMINISTERED WITH EDURANT.', 'H 2 -RECEPTOR ANTAGONISTS : CIMETIDINE FAMOTIDINE NIZATIDINE RANITIDINE', '\xe2\x86\x94 RILPIVIRINE (FAMOTIDINE TAKEN 12 HOURS BEFORE RILPIVIRINE OR 4 HOURS AFTER RILPIVIRINE)', 'THE COMBINATION OF EDURANT AND H 2 -RECEPTOR ANTAGONISTS SHOULD BE USED WITH CAUTION AS CO-ADMINISTRATION MAY CAUSE SIGNIFICANT DECREASES IN RILPIVIRINE PLASMA CONCENTRATIONS (INCREASE IN GASTRIC PH). H 2 -RECEPTOR ANTAGONISTS SHOULD ONLY BE ADMINISTERED AT LEAST 12 HOURS BEFORE OR AT LEAST 4 HOURS AFTER EDURANT.', '', '\xe2\x86\x93 RILPIVIRINE (FAMOTIDINE TAKEN 2 HOURS BEFORE RILPIVIRINE)', '', 'MACROLIDE OR KETOLIDE ANTIBIOTICS : CLARITHROMYCIN ERYTHROMYCIN TELITHROMYCIN', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 CLARITHROMYCIN \xe2\x86\x94 ERYTHROMYCIN \xe2\x86\x94 TELITHROMYCIN', 'CONCOMITANT USE OF EDURANT WITH CLARITHROMYCIN, ERYTHROMYCIN OR TELITHROMYCIN MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). WHERE POSSIBLE, ALTERNATIVES SUCH AS AZITHROMYCIN SHOULD BE CONSIDERED.', 'NARCOTIC ANALGESICS : METHADONE', '\xe2\x86\x93 R(-) METHADONE \xe2\x86\x93 S(+) METHADONE', 'NO DOSE ADJUSTMENTS ARE REQUIRED WHEN INITIATING CO-ADMINISTRATION OF METHADONE WITH EDURANT. HOWEVER, CLINICAL MONITORING IS RECOMMENDED AS METHADONE MAINTENANCE THERAPY MAY NEED TO BE ADJUSTED IN SOME PATIENTS.']